ArticleScientific reports2025
Survival and prognostic factors among different types of liposarcomas based on SEER database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.ESMO open · 2026Trial
- Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma.Current treatment options in oncology · 2026Review
- Soft tissue and juxtaarticular tumors of the knee.Skeletal radiology · 2026Review
- Perihepatic dedifferentiated liposarcoma mimicking IgG4-related disease.Clinical journal of gastroenterology · 2026Article
- Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting.Cancer medicine · 2026Observational
- Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review.Frontiers in oncology · 2026Article
- Development and temporal validation of a machine learning-based model to predict postoperative recurrence and guide adjuvant radiotherapy in patients with soft tissue sarcoma: a retrospective cohort study.American journal of cancer research · 2026Article
- Features of MR Imaging that Differentiate between Immunohistochemically Diagnosed Dedifferentiated Liposarcoma and Myxoid Liposarcoma.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Article
- Clinicopathological Characteristics and Survival Analysis of Primary Mesenteric Liposarcoma: A Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Histomorphological and molecular characteristics of liposarcoma (Review).Oncology letters · 2025Review
- Myxoid Liposarcoma of the Thigh in Early Puerperium-Rare Case Report and Narrative Review.Diseases (Basel, Switzerland) · 2025Article
- Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.Future oncology (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data. The study cohort consisted of 12,822 patients diagnosed with liposarcoma in the United States between 2000 and 2021, whose data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program. The prognosis for different subtypes of liposarcoma and the associated factors such as age, tumor stage, intervention, gender, tumor grade, location, size, chemotherapy and radiotherapy, were retrieved from the database. Well-differentiated liposarcoma demonstrated the most favorable prognosis, with 5-year and 10-year survival rates of 82% and 68%, respectively, followed by myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma, which exhibited the poorest prognosis. Advanced age, higher tumor stage, and the absence of surgical intervention were associated with inferior survival outcomes across all subtypes. Male gender, higher pathological grade, and primary tumor sites outside the extremities were identified as risk factors for the prognosis of subtypes other than pleomorphic liposarcoma. Larger tumor size was an indicator of a worse prognosis in subtypes other than well-differentiated liposarcoma. Chemotherapy was a risk factor for the prognosis of well-differentiated and myxoid liposarcomas but had no significant correlation with the prognosis of pleomorphic and dedifferentiated liposarcomas. Radiotherapy served as a protective factor for the prognosis of subtypes other than well-differentiated liposarcoma. Survival and prognostic factors vary among the major subtypes of liposarcoma, necessitating individualized analysis for each subtype. Poorer outcomes can be anticipated in the dedifferentiated and pleomorphic subtypes, while well-differentiated and myxoid liposarcomas exhibit relatively favorable prognoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.